SCHEMBL3976153

SCHEMBL3976153

CCN(CC)CCCNc1nc(-c2ccc(NC(=O)CC(C)C)cc2)nc2cc(Cl)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.58
FLT3 P36888 6/20 0.57
PDGFRB P09619 1/20 0.57
KIT P10721 1/20 0.57
PIK3CA P42336 1/20 0.57
POLB P06746 2/20 0.50
SENP7 Q9BQF6 1/20 0.49
CASP3 P42574 1/20 0.49
KDM1A O60341 1/20 0.46
PARP3 Q9Y6F1 1/20 0.46
TERT O14746 1/20 0.45
TP53 P04637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 1/20 0.44
HMOX1 P09601 1/20 0.43
CDK1 P06493 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980449 0.83 SLC2A1 (0.78) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL6670648 0.81 SLC2A1 (0.80) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3972870 0.81 SLC2A1 (0.70) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3979948 0.81 SLC2A1 (0.60) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3975359 0.80 SENP7 (0.61) SENP7CASP3KDM1ATP53ALDH1A1
SCHEMBL3974647 0.78 FLT3 (0.70) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3976619 0.77 SLC2A1 (0.64) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3972522 0.76 SLC2A1 (0.63) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL3973291 0.75 SLC2A1 (0.64) SLC2A1FLT3PDGFRBKITPIK3CA
SCHEMBL6671471 0.75 SLC2A1 (0.70) SLC2A1FLT3POLBTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 SLC2A1 1107/4885FLT3 1822/4885PDGFRB 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.